secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2023-07-25T23:59:59+00:00
Accession:  0001193125-23-192827
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Tarsus' XDEMVY (lotilaner) 0.25% for Demodex blepharitis
---------------------------------------------------------------------

- FDA approved XDEMVY (lotilaner ophthalmic solution) 0.25% for treatment of Demodex blepharitis.
- Approval announced July 25, 2023 via press release and investor webcast.
- Corporate presentation and webcast replay posted on Tarsus' investor website.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000119312523192827/0001193125-23-192827-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000119312523192827/d540952d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-192827

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer